METYRAPONE HRA PHARMA (metyrapone), treatment of endogenous Cushing’s syndrome and test for pituitary function

ENDOCRINOLOGY - New medicinal product
Opinions on drugs - Posted on Nov 04 2016

Reason for request

Inclusion

Minor improvement in the treatment of endogenous Cushing’s syndrome.

No clinical benefit demonstrated as a dynamic test exploring the function of the hypothalamic-pituitary-adrenal axis.

  • METYRAPONE HRA PHARMA has Marketing Authorisation in the treatment of patients with endogenous Cushing’s syndrome, the diagnosis of ACTH deficiency, and the differential diagnosis of ACTH-dependent Cushing’s syndrome.
  • The data from clinical studies offer low levels of proof in the treatment of Cushing’s syndrome without any convincing demonstration of benefit in terms of diagnostic performance.
  • Metyrapone’s delayed action is short, with a plasma peak reached in 1 hour.
  • It forms part of the arsenal of protocols exploring the function of the hypothalamic-pituitary-adrenal axis. 

 

 


Clinical Benefit

Substantial

-


Clinical Added Value

minor

-

no clinical added value

Therapeutic use

-

Contact Us

Évaluation des médicaments